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Letters e61Due to suspicion that psoriasis was induced by
INF-, therapy was discontinued; however, the skin
lesions did not resolve. PASI score was 21, BSA was
18%, and PGA was 3. There was no improvement
with UVB phototherapy. Finally, treatment with
fumaric acids was chosen. Fumaric acids are an
approved therapeutic option for psoriasis and are
under investigation for use in cases of MS.
Treatment was started with the recommended
dose for psoriasis, that is, 30 mg/day and gradually
increased to 480 mg/day. Within 6 weeks, PASI
score was improved by 75% (Fig 2). Expected
adverse events such as nausea, diarrhea, and hot
flushes were seen, although the dosing regimen
remained unaltered. After more than 18 months on
treatment with fumarates, the patient’s psoriatic
lesions are stable and no new neurologic symp-
toms have developed. MRI of the brain showed no
further disease progression.
MS is an inflammatory demyelinating disorder
thought to be triggered by autoreactive T cells.
Like psoriasis, it is thought to be a Th1 cell
disease.5 Although it is a very effective therapy
for psoriasis, treatment with biologic agents of the
anti-tumor necrosis factor- group could evoke or
exacerbate preexisting MS. This makes the com-
bination of psoriasis and multiple sclerosis to be a
very challenging situation with respect to man-
agement.6 In the past few years, the oral agent
DMF BG-12 has been investigated for the treat-
ment of MS. In our case, fumaric acids were
efficacious and well tolerated in both psoriasis
and clinically isolated syndrome with a high risk
for MS development. No progression of multiple
sclerosis was observed, which allows us to
consider the use of a single treatment option in
the future for patients simultaneously affected by
both diseases.
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Hemagglutination during photopheresis
To the Editor: Cold agglutinin disease (CAD) is an
uncommon form of autoimmune hemolytic anemia
that results from complement fixation to IgM agglu-
tinated red blood cells (RBCs).1 These IgM anti-
bodies are known as cold agglutinins (CAs) because
they react at cold temperatures with RBC surface
antigens.2,3 Although hemagglutination has been
reported during cardiopulmonary bypass, there are
no reports of this complication with extracorporeal
photopheresis (ECP).4,5 We present a case of hem-
agglutination that occurred in a patient with CAD
receiving ECP.
The patient was a 73-year-old white man with
Sezary syndrome (SS) undergoing treatment with
bexarotene and ECP. His medical history was signif-
icant for chronic lymphocytic leukemia (CLL) and
chronic macrocytic anemia, which was attributed to
the former. Work-up of the anemia included normal
B12 and folate results and normal colonoscopy.
Following a severe outbreak of herpes zoster, the
patient was receiving his 25th treatment of ECPwhen
agglutinated blood was noted in the centrifuge bowl,
acrylic plates, and tubing. A hemoglobin level
obtained at that time was 7.1 g/dL. A direct
Coombs test was positive for anti-C3d and negative
for anti-IgG, confirming the diagnosis of cold
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complications.
Review of themedical records revealed that in 9 of
the patient’s complete blood counts over the previ-
ous 2 years, the laboratory had commented that the
patient’s blood sample ‘‘required rewarming’’ and
appeared ‘‘markedly agglutinated.’’ Laboratory re-
sults from the previous year showed a progressive
decrease in hemoglobin and gradual increases in
lactate dehydrogenase and mean corpuscular vol-
ume, indicating progression of CAD. An increase in
the CD4-to-CD8 ratio was also observed, indicating
simultaneous progression of SS. These findings sug-
gest that the patient may have had pathologic CAs
causing low-grade hemolysis and agglutination for 2
years while undergoing ECP.
The incidence of CAD is 1 per million per year,
and the disease is divided into primary and second-
ary subtypes.1 Primary CAD is monoclonal, chronic,
and associated with lymphoproliferative malig-
nancies, most frequently CLL. Secondary CAD is
transient, polyclonal, and associated with viral and
mycoplasma infections.1 CAs are found at low levels
in the sera of most healthy individuals and react at
low temperatures. They may become pathologic at
high titers or high thermal amplitudes, the temper-
ature at which the autoantibodies react.1-4 Activation
of CAseprecipitated by exposure to low tempera-
tures and acute phase reactantsecan result in cold-
induced circulatory symptoms such as acrocyanosis,
as well as catastrophic hemagglutination and hemo-
lysis.1,2 Clues to the diagnosis of CAD in our patient
include chronic macrocytic anemia, a history of CLL,
and temperature-dependent hemagglutination.1-5
Although his CAD and SS were progressing simulta-
neously, there are no reports of a correlation be-
tween the 2 conditions. We attribute the patient’s
CAD to his underlying CLL. Hemagglutination may
have been precipitated by his recent viral illness and
environmental conditions during ECP. We have
presented a potentially serious complication that
occurred during the use of a therapy that is broadly
applied by multiple medical specialties. Awareness
of the risk factors, signs, and symptoms of CAD, and
appropriate pretreatment screening may help avoid
this rare but significant adverse event in patients with
CAs undergoing ECP.
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concomitant anti-MDA5 features
To the Editor:Dermatomyositis (DM) is amultisystem
autoimmune disease for which multiple phenotypes
have been described. Here we report the case of a
patient with both Wong-type DM and features of a
DM phenotype associated with anti-melanoma
differentiation-associated gene 5 antibodies (anti-
MDA5 DM).
A previously healthy 54-year-old man presented
with a 1-year history of a progressive eruption
previously diagnosed as pityriasis rubra pilaris
(PRP) by 2 independent dermatologists. He had
failed topical corticosteroids and 2 courses of oral
prednisone pulses, and subsequently weakness and
dyspnea on exertion developed. His past medical
history was unremarkable.
Exam revealed confluent pink-orange patches
and plaques over the trunk with islands of sparing
(Fig 1), and his extremities displayed hyperkeratotic
follicular papules. He also had painful violaceous
palmar papules (Fig 2), ragged cuticles, rough radial
palms and digits, and subtle violaceous periorbital
edema. Proximal muscle strength was 4-51.
